BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 6713410)

  • 1. Variations in committed stem cells (CFU-GM and CFU-TL) in the peripheral blood of cancer patients treated by sequential combination chemotherapy for breast cancer.
    Rusé-Riol F; Legros M; Bernard D; Chassagne J; Clavel H; Ferriere JP; Chollet P; Plagne R
    Cancer Res; 1984 May; 44(5):2219-24. PubMed ID: 6713410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
    Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
    Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma.
    Tarella C; Boccadoro M; Omedé P; Bondesan P; Caracciolo D; Frieri R; Bregni M; Siena S; Gianni AM; Pileri A
    Bone Marrow Transplant; 1993 Apr; 11(4):271-7. PubMed ID: 7683551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells.
    Roman-Unfer S; Bitran JD; Garrison L; Proeschel C; Hanauer S; Schroeder L; Johnson L; Klein L; Martinec J
    Exp Hematol; 1996 Jun; 24(7):823-8. PubMed ID: 8647233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematological recovery and peripheral blood progenitor cell mobilization after induction chemotherapy and GM-CSF plus G-CSF in breast cancer.
    Charrier S; Chollet P; Bay JO; Curé H; Kwiatkowski F; Portefaix G; Communal Y; Bétail G; Plagne R; Chassagne J
    Bone Marrow Transplant; 2000 Apr; 25(7):705-10. PubMed ID: 10745254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma].
    Garrone O; Del Mastro L; Mariani GL; Ardizzoni A; Venturini M; Rosso R
    Minerva Med; 1993 Sep; 84(9):467-72. PubMed ID: 7504219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.
    Schneider JG; Crown JP; Wasserheit C; Kritz A; Wong G; Reich L; Norton L; Moore MA
    Bone Marrow Transplant; 1994 Dec; 14(6):877-84. PubMed ID: 7536069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
    Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mobilization of autologous peripheral blood stem cells by combined chemotherapy and rhG-CSF].
    Shi H; Gu X; Zhu L
    Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):159-61. PubMed ID: 11783025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy.
    Waller CF; von Lintig F; Daskalakis A; Musahl V; Lange W
    Bone Marrow Transplant; 1999 Jul; 24(1):19-24. PubMed ID: 10435729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
    Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
    Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer.
    Weaver CH; Schwartzberg LS; Birch R; Greco FA; Hainsworth J; Drapkin R; Campos L; Grapski R; Schwerkoske J; Lautersztain J; Hazelton B; Schnell F; Babcock W; Buckner CD
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):83-90. PubMed ID: 9267668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
    Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
    Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Favorable effect of hematopoietic stem cells isolated from blood on hematologic recovery following high-dosage chemotherapy].
    Richel DJ; Baars JW; Wijngaarden MJ; van der Schoot CE; Vlasveld LT; Rodenhuis S
    Ned Tijdschr Geneeskd; 1993 Jan; 137(5):245-50. PubMed ID: 7679478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
    Janikova A; Koristek Z; Vinklarkova J; Pavlik T; Sticha M; Navratil M; Kral Z; Vasova I; Mayer J
    Exp Hematol; 2009 Nov; 37(11):1266-73. PubMed ID: 19654036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
    Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
    Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.